Literature DB >> 1721640

The VLA-4/VCAM-1 pathway is involved in lymphocyte adhesion to endothelium in rheumatoid synovium.

A C van Dinther-Janssen1, E Horst, G Koopman, W Newmann, R J Scheper, C J Meijer, S T Pals.   

Abstract

Lymphocyte migration to inflammatory sites is an essential factor in the pathogenesis of chronic inflammation. An ensemble of adhesion receptors mediating lymphocyte-endothelial cell recognition and binding are thought to play a crucial role in this process. In the present study, we have explored the molecular basis of lymphocyte adhesion to endothelium in the synovial membrane of patients with rheumatoid arthritis. We established that the very late antigen-4 [VLA-4 (CD49d)] and the vascular cell adhesion molecule-1 (VCAM-1) are important mediators of binding to synovial endothelium of resting and, to a greater extent, of activated T lymphocytes, whereas the leukocyte-function associated antigen-1 [LFA-1 (CD11a/18)]/intercellular adhesion molecule-1 [ICAM-1 (CD54)] pathway is less important in this interaction. In contrast to its prominent role in lymphocyte interaction with endothelium in rheumatoid synovium, the VLA-4/VCAM-1 pathway does not significantly contribute to lymphocyte adhesion to peripheral lymph node high endothelial venule. Thus, the VLA-4/VCAM-1 pathway may be of primary importance in mediating lymphocyte adhesion to inflamed endothelium and in lymphocyte homing to rheumatoid synovium.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1721640

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  43 in total

1.  Vascular cell adhesion molecule-1 (VCAM-1) blockade in collagen-induced arthritis reduces joint involvement and alters B cell trafficking.

Authors:  R A Carter; I K Campbell; K L O'Donnel; I P Wicks
Journal:  Clin Exp Immunol       Date:  2002-04       Impact factor: 4.330

2.  B-cell activation by membrane-bound antigens is facilitated by the interaction of VLA-4 with VCAM-1.

Authors:  Yolanda R Carrasco; Facundo D Batista
Journal:  EMBO J       Date:  2006-02-02       Impact factor: 11.598

3.  Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice.

Authors:  U Müller-Ladner; J Kriegsmann; B N Franklin; S Matsumoto; T Geiler; R E Gay; S Gay
Journal:  Am J Pathol       Date:  1996-11       Impact factor: 4.307

4.  Neovascularisation and the induction of cell adhesion molecules in response to degradation products from orthopaedic implants.

Authors:  N al-Saffar; J T Mah; Y Kadoya; P A Revell
Journal:  Ann Rheum Dis       Date:  1995-03       Impact factor: 19.103

5.  Expression of vascular cell adhesion molecule (VCAM-1) in liver and pancreas allograft rejection.

Authors:  C E Bacchi; C L Marsh; J D Perkins; R L Carithers; J P McVicar; K L Hudkins; C D Benjamin; J M Harlan; R Lobb; C E Alpers
Journal:  Am J Pathol       Date:  1993-02       Impact factor: 4.307

Review 6.  Adhesion molecules in rheumatoid arthritis.

Authors:  N Oppenheimer-Marks; P E Lipsky
Journal:  Springer Semin Immunopathol       Date:  1998

7.  Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody.

Authors:  D K Podolsky; R Lobb; N King; C D Benjamin; B Pepinsky; P Sehgal; M deBeaumont
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

8.  Cytokine induction of an alternatively spliced murine vascular cell adhesion molecule (VCAM) mRNA encoding a glycosylphosphatidylinositol-anchored VCAM protein.

Authors:  R W Terry; L Kwee; J F Levine; M A Labow
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

9.  Canonical Wnt pathway signaling suppresses VCAM-1 expression by marrow stromal and hematopoietic cells.

Authors:  Sachin Malhotra; Paul W Kincade
Journal:  Exp Hematol       Date:  2008-10-25       Impact factor: 3.084

10.  In vitro differentiation of peripheral blood T cells towards a type 2 phenotype is impaired in rheumatoid arthritis (RA).

Authors:  S Asselin; H Conjeaud; D Fradelizi; M Breban
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.